These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Survival after immunosuppressive therapy in children with aplastic anemia.
    Author: Nair V, Sondhi V, Sharma A, Das S, Sharma S.
    Journal: Indian Pediatr; 2012 May; 49(5):371-6. PubMed ID: 22080620.
    Abstract:
    OBJECTIVE: To determine the survival of children =18 y, treated with immunosuppressive therapy (IST) using equine antithymocyte globulin (e-ATG) and cyclosporine (CsA). DESIGN: Prospective data entry as per a specified format. SETTING: Tertiary care hospital. PATIENTS: From January 1998 to December 2009, 40 children were diagnosed with acquired aplastic anemia; 33 patients, who received IST, were analyzed. 31 children (94%) received one course of e-ATG and CsA. 2 patients (6%) received two courses of ATG. INTERVENTION: Immunosuppressive therapy using equine ATG and cyclosporine. MAIN OUTCOME MEASURES: Overall response and overall survival. RESULTS: The overall response (complete response + partial response) to IST at 6 months was 87.9%. 8 (24.2%) patients achieved CR, 21 (63.6%) patients had PR and 4 (12.1%) patients did not respond to IST. Median follow-up was 24 (6-102) months. Overall survival at 24 months was 90%, with an actual survival of 85.4% at 5 years. Seventeen patients (51.5%) received G-CSF for a median duration of 32 (23-64) days. The patients who received G-CSF had fewer infectious complications (P=0.002), but G-CSF administration did not influence survival/ outcome. No patient developed myelodysplastic syndrome or acute leukemia. CONCLUSIONS: The survival of patients who respond to IST is excellent. Also, G-CSF reduces the infectious complications without conferring any survival advantage.
    [Abstract] [Full Text] [Related] [New Search]